Lee, M. M.Y. , Kristensen, S. L., Gerstein, H. C., McMurray, J. J.V. and Sattar, N. (2022) Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 16(1), 102382. (doi: 10.1016/j.dsx.2021.102382) (PMID:35030451)
Full text not currently available from Enlighten.
Abstract
Background and aims: FREEDOM, a cardiovascular outcome trial with a GLP-1 receptor agonist, testing a continuous subcutaneous infusion of exenatide (ITCA 650), recently reported its findings. Methods: We meta-analysed its results with eight prior GLP-1 receptor agonists trials. Results: GLP-1 receptor agonists reduced MACE by 13% (HR 0.87 [95% CI 0.81–0.94]; p = 0.00065) and all-cause mortality by 11% (HR 0.89 [0.83–0.95]; p = 0.00084). However, FREEDOM results appear dissimilar to prior GLP-1 receptor agonist trials. Conclusion: FREEDOM results should not influence current considerations about the benefits or harms of approved formulations of GLP-1 receptor agonists. There is also an ongoing debate about the safety of ITCA 650.
| Item Type: | Articles |
|---|---|
| Keywords: | GLP-1 receptor agonists, diabetes, cardiovascular disease. |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Kristensen, Mr Soren Lund and Lee, Matthew and Sattar, Professor Naveed and McMurray, Professor John |
| Authors: | Lee, M. M.Y., Kristensen, S. L., Gerstein, H. C., McMurray, J. J.V., and Sattar, N. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | Diabetes and Metabolic Syndrome: Clinical Research and Reviews |
| Publisher: | Elsevier |
| ISSN: | 1871-4021 |
| ISSN (Online): | 1878-0334 |
| Published Online: | 28 December 2021 |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information